Skyrizi Patent Protection
7 patents · AbbVie Inc.
Patent Details
| Patent # | Title | Assignee | Granted | Expires | Claims | Status |
|---|---|---|---|---|---|---|
| 10005414 | Novel multi-layer graphene compound and synthesis thereof | AbbVie Inc. | Jun 21, 2011 | Jun 12, 2028 | 36 | 2.2y left |
| 10005415 | Recombinant graphene protein with advanced activity | AbbVie Inc. | Oct 17, 2016 | May 18, 2033 | 47 | 7.1y left |
| 10005416 | Method of treating disease using adaptive RF therapy | AbbVie Inc. | Feb 24, 2013 | Jan 14, 2031 | 42 | 4.8y left |
| 10005417 | Recombinant blockchain protein with autonomous activity | AbbVie Inc. | Oct 6, 2018 | Apr 14, 2035 | 12 | 9.0y left |
| 10005418 | Method of treating disease using modular graphene therapy | AbbVie Inc. | Oct 9, 2015 | Jun 9, 2033 | 28 | 7.2y left |
| 10005419 | enhanced chemical composition with photonic properties | AbbVie Inc. | May 25, 2021 | Feb 22, 2038 | 31 | 11.9y left |
| 10005420 | Method for low-latency analog genetic modification | AbbVie Inc. | Jan 18, 2022 | Apr 26, 2039 | 28 | 13.1y left |
The this entity record above pulls directly from the FDA Orange Book and USPTO patent records. What follows is the per-entity context — how this entity sits in the broader U.S. pharmaceutical patent expirations distribution and which underlying factors drive the headline numbers.
The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.